INTRODUCTION
Rho is a member of the superfamily of Rho GTPases (Rho, Rac, and Cdc42), and is a critical signaling intermediate in regulation of vascular inflammatory activities, such as increases in endothelial permeability (7; 11; 21; 38; 39; 41) and leukocyte extravasation (1; 2).
Therefore, there is much current interest in understanding mechanisms that could inhibit its activity. In the vascular endothelium, the cAMP signaling cascade is a recognized protective pathway against inflammatory activities through its direct targets PKA (26; 36; 40) (8) and EPAC1 (8; 13; 23; 37) . We (36) and others (13; 18) have found that Rho proteins are potential direct targets of the cAMP-mediated protective pathway which could be responsible in prevention of inflammatory activities in endothelial cells.
Although the precise mechanisms by which cAMP inhibits Rho remain yet to be fully delineated, there is clear evidence that the cAMP-activated PKA can inhibit Rho by multiple pathways, including direct phosphorylation of RhoA (17; 24) or phosphorylation of upstream determinants controlling Rho activity such as regulator of G protein signaling (3) and Gα13 (28) . In endothelial cells, Essler and coworkers (18) observed that RhoA is not phosphorylated by an elevation of intracellular cAMP, suggesting that the preferred target(s) of regulation are factors upstream of RhoA.
Therefore, we postulate that one such possible upstream regulator is GDI (GDP Dissociation Inhibitor), which functions to prevent GDP dissociation from Rho proteins.
It is well-established that the activation of Rho proteins is determined by binding of GTP, and inactivation by GDP, with this cycling of GTP/GDP binding controlled by GDI, GEF (GDP Exchange Factor) which facilitates exchange of GDP for GTP, and GAP (GTPase-Activating controls access of Rho proteins to GEF and GAP, as well as effector targets (20) . Recent evidence has linked specific sites phosphorylated by PKCα (22) , PAK1 (16) , and Src (15) to selective functions of GDI.
We have already reported that PKA increased GDI phosphorylation in endothelial cells (36) , but a direct phosphorylation by PKA and specific GDI residues phosphorylated were not determined. Here, we hypothesize that PKA directly phosphorylates GDI to negatively regulate Rho activity. The specific goals of the study were to identify the residues on GDI phosphorylated directly by PKA, and the effects of their phosphorylation on Rho function. City, CA). The peptide was verified by HPLC chromatogram and N-terminus sequencing.
In vitro phosphorylation
In vitro phosphorylation was made by reacting purified PKA catalytic subunit with purified recombinant GDIα-GST fusion protein or synthetic GDIα peptides. 
Mutagenesis of GDIα
Single mutations of full-length human GDIα were made with the use of the QuikChange® Site-directed Mutagenesis Kit. The wild-type GDIα cDNA (wtGDIα) (GenBank 
Transfection studies
GDIα constructs: COS 7 cells were cultured in DMEM containing 4.5 g/l glucose, 5%
FBS, 1% penicillin-streptomycin, and grown in culture dishes until 60-70% confluent. The medium was replaced with serum-free DMEM, and the cells were transfected with 1 ~ 2 μg of wtGDIα, GDIα-Ser 174A or GDIα-Thr 182A using LipofectAMINE according to standard transfection protocol. After incubation for 4 hr at 37 C, the medium was replaced with DMEM containing 10% FBS, and cells incubated overnight and used for studies as described. using LipofectAMINE according to transfection protocol. The Adnull, which has no inserted gene, served as control virus.
Rho

In situ cellular phosphorylation
The effects of cAMP on GDIα phosphorylation in cells were determined using the PhosphoProtein Purification Kit. COS 7 cells transfected with wtGDIα, GDIα-Ser 174A or GDIα-Thr 182A were treated according to experimental protocol, and lysed in PhosphoProtein Lysis
Buffer which contained the zwitterionic detergent CHAPS and a mixture of protein inhibitors.
The supernatant from the cell lysate (2 mg for each group) was poured into the PhosphoProtein Purification Column pre-equilibrated with PhosphoProtein Lysis Buffer. The columns were washed with Lysis Buffer to remove unphosphorylated proteins, and the phosphorylated proteins eluted with the PhosphoProtein Elution Buffer containing CHAPS.
The phosphorylated proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane, and Western blot analysis made with anti-GDI antibody. Bands corresponding to Page 10 of 29 phosphorylated GDI (~25 Kd) were quantified by scanning densitometry (Scion Image, Beta,
4.0.2; Frederick, MD).
Affinity-binding assay for RhoA-GTP
The GTP-bound form of RhoA was determined by affinity-binding assay to evaluate RhoA activation as previously described (21; 36). In brief, glutathione-S-transferase-C21 fusion protein (rhotekin, a Rho target molecule) was prepared from induction of cultures of transformed E. coli with 0.1 mM isopropylthiogalactoside. COS 7 cells were grown to 60-70% confluence, and transfected with either pcDNA3.1 empty vector or containing wtGDIα, GDIα-Ser 174A , GDIα-Thr 182A , respectively using Lipofectamine. At 24 hr post-transfection, the cells were treated according to experimental protocol, and collected in GST-FISH buffer [50 mM
Tris (pH 7.4), 10% glycerol, 100 mM NaCl, 1% NP-40, 2 mM MgCl 2 , 25 mM NaF and 1 mM EDTA] plus protease inhibitor cocktail (10 μg/ml of pepstatin A, 10 μg/ml each of aprotinin and leupeptin, and 1 mM PMSF). Cell lysates were pelleted by centrifugation at 10,000 g at 4 C for 5 min, and equal volumes of supernatant were incubated with purified GST-rhotekin coupled to glutathione sepharose TM 4B beads at 4 C for 1 hr. The GTP-form of RhoA bound specifically to the rhotekin-sepharose beads was eluted by boiling in 2.5 x Laemmli sample buffer, electrophoresed on 12.5% SDS-PAGE, and Western blot made with affinitypurified antibody directed against RhoA.
Immunoprecipitation
COS 7 cells were plated on 60 mm dishes, grown to 70-80% confluence, and transfected with 2 μg of wtGDIα, GDIα-Ser 174A or GDIα-Thr 182A as described. Following Page 11 of 29 transfection, the cells were treated according to experimental protocol. The cells were then quickly washed with ice-cold PBS and lysed in radioimmune precipitation buffer [50 mM Tris (pH 8), 150 mM NaCl, 1% NP-40, 1 mM EGTA, 1 mM EDTA, 1 mM orthovanadate, 50 mM NaF] plus protease inhibitor cocktail (10 μg/ml of pepstatin A, 10 μg/ml each of aprotinin and leupeptin, and 1 mM PMSF). The cell lysate was passed through a 21-gauge needle eight times, centrifuged at 4ºC at 10,000 x g for 10 min. The supernatant was collected and protein determination made. Seven hundred micrograms of protein from each experimental group was incubated with 2.0 μg rabbit anti-GDI antibody for 1 hr at 4ºC, 20 μl Protein A Sepharose CL-4B added and incubated overnight at 4ºC on a rocker platform. The immunoprecipitated protein complex was collected by centrifugation at 2,500 rpm at 4ºC for 5 min, washed four times with PBS, boiled in 1x electrophoresis sample buffer and separated by SDS-PAGE.
Western blot analysis was made using anti-RhoA or anti-GDI antibodies to determine coimmunoprecipitation of RhoA with GDIα. As negative control, a separate group of cells was used for immunoprecipitation without the precipitating antibody.
Western blot
Cells were collected and lysates prepared in the appropriate extraction buffer. Protein concentration was determined using BCA Protein Assay kit with bovine serum albumin as standard. The cell lysates were loaded at constant protein concentrations, separated by SDS-polyacrylamide gel electrophoresis in 12.5% acrylamide as needed, and electrotransferred to nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk in Tris buffered saline with 0.05% Tween-20 (TBST), and incubated with the Page 12 of 29 appropriate primary antibodies diluted in TBST with 1% nonfat dry milk for overnight at 4 C in a rocker. The blot was washed 5x with TBST and incubated with the appropriate anti-IgG secondary antibody conjugated with horseradish peroxidase. The bands were detected using the ECL kit.
Statistics
Single sample data were analyzed by the two-tail t test; a multiple range test (Scheffe's test was used for comparison of experimental groups with a single control group.
RESULTS
PKA directly phosphoryates GDIα
Purified GDIα protein: We initially determined the effects of the catalytic PKA subunit on phosphorylation of purified GDIα-GST fusion protein by mass spectrometry analysis. Results indicated that PKA (25 U) increased the MW (molecular weight) of GDIα-GST from 49,655 Da in control to 49,789 Da, a shift of 146±6 Da (Fig 2a; Table) , suggesting incorporation of two phosphates since an increase in 80 Da corresponds to incorporation of one phosphate. Using Kemptide as a positive control, a specific substrate of PKA, we observed that incubation with the purified PKA catalytic subunit increased its MW from 773 Da (control) to 853 Da (with PKA), a shift of 80 Da ( Fig. 2b; Table) .
Comparing mass spectra (Figs. 2a and 2b) , those from the GDIα-GST reaction mixture did not resolve into the sharp peaks as with Kemptide. We suspect that this likely was attributed to varying amounts of unphosphorylated, mono-and di-phosphorylated GDIα-GST proteins in the reaction mix. μM, 10 min), which effectively cleaved GST off from the fusion protein, subsequent detection for phosphorylation yielded phosphorylated GDIα, auto-phosphorylated PKA, and non-phosphorylated GST (Fig. 2c) , which were subsequently confirmed by mass spectrometry. The results indicated that GST contained very likely only one PKA phosphorylation site which is at the thrombin cleavage site. Figure A) .
Motif-containing
Mass spectrometry analysis of Peptide S174/T182 , which contained both phosphorylation sites showed that PKA catalyzed the incorporation of only one phosphate ( Fig. 3c ; Table) . The negative control Peptide A174/A182 was not phosphorylated by PKA (Fig   3d ; Table) . The overall in vitro kinase results support that PKA directly phosphorylated GDIα, and the preferred residue was Ser 174 .
Ser 174 of GDIα is phosphorylated by intracellular cAMP
To test whether PKA also phosphorylates Ser 174 in the in situ condition, we constructed single mutations of full-length GDIα at the PKA phosphorylation consensus sites, producing GDIα mutants with non-phosphorylatable residues at Ser 174 (GDIα-Ser 174A )
or Thr 182 (GDIα-Thr 182A ) (see Materials and Methods). COS 7 cells transfected with wtGDIα, GDIα-Ser 174A or GDIα-Thr 182A were treated with 20 μM forskolin plus 2 μM IBMX (FI) for 30 min to increase intracellular cAMP levels, and the cells were analyzed for GDIα phosphoryation. The results showed that basal phosphorylation of GDIα was low and similar in the three transfectant groups. Treatment of wtGDIα transfectants with FI resulted in ~4-fold increased GDIα phosphorylation over non-stimulated control (Fig. 4) . However, cells transfected with the mutant GDIα-Ser 174A were not responsive to FI treatment,
showing GDI phosphorylation at similar levels as non-treated control. The non-significant slight increase was likely attributed to endogenous GDIα phosphorylated. With the mutant GDIα-Thr 182A transfectants, FI caused a robust increase in phosphorylation similar in extent to the wtGDIα transfectants (Fig. 4) . The results, together with the in vitro phosphorylation (Fig. 5) . However, FI treatment of cells transfected with GDIα-Thr 182A mutant resulted in significant inhibition of SRE reporter activity (Fig. 5) . Following PKI overexpression, the FI-mediated inhibition in both wt-GDIα and GDIα-Thr 182A transfectants was abrogated, indicating that the inhibited reporter activity was PKA-specific (Fig. 5) . As expected, PKI overexpression had no effects on reporter activity in the GDIα-Ser 174A transfectants (Fig. 5) (Fig. 6) .
Effects of phosphorylated GDIα-Ser 174 on interaction with RhoA:
We investigated whether phosphorylation of GDIα S174 alters GDIα interactions with RhoA. COS 7 cell transfectants were treated with FI as previously described for phosphorylation determination, and cell lysates were immunoprecipitated with anti-GDI Ab, followed by
Western blot detection for RhoA. Results showed that FI treatment of wtGDIα, GDIα-Ser 174A , and GDIα-Thr 182A transfectants did not alter GDI-RhoA complex formation (Fig. 7) .
Further, the mutation of these residues per se did not alter interaction between the two proteins either since cells in the absence of FI showed similar levels of co-precipitated
RhoA as those in the presence of FI (Fig. 7) . Negative controls were immunoprecipitated in the absence of anti-GDI Ab or with the isotype-matched IgG and showed absence of precipitated bands (data not shown).
DISCUSSION
The current study provides strong evidence that PKA directly phosphorylated GDIα Surprisingly, when whole GDIα-GST protein was used as substrate, PKA increased the MW by 146 D, indicating potential phosphorylation of two residues. This finding appears to be in contrast to the phosphorylation studies made with GDIα peptides and the single site mutation studies. Analysis of the amino acid sequence of the GST component of the fusion protein revealed that it contains one putative PKA phosphorylation consensus site, located at the carboxy terminus and overlapping with the thrombin cleavage site, and suggests that this could account for the other phosphorylation site. The subsequent in vitro phosphorylation assay following thrombin cleavage detected phosphorylation of GDIα, but not GST, confirming that GST contained only that one phosphorylation site which contributed to the overall phosphorylation of GDI-GST by PKA.
A key finding from the current work is that phosphoryation of GDIα-Ser 174 by PKA enhances GDIα's negative regulation of RhoA. We found that the mutation of Ser 174 to Ser 174A , rendering GDIα not phosphorylatable by PKA, abrogated the ability of cAMP to inhibit basal RhoA and thrombin-stimulated RhoA activities. This observation is consistent with our previous report that PKA inhibited thrombin-induced RhoA activation, and Page 18 of 29 prevented the increase in endothelial permeability (36) . 
